It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look ...

The two companies’ applications for China-approved PD-1 inhibitor camrelizumab and the VEGFR tyrosine kinase inhibitor ...

Just seven weeks after projecting an 18% revenue boost for this year, Indivior has slashed its estimate to an 8% increase, ...

Roche has claimed the top spot in a ranking of the online presence of drugmakers, climbing two spots on the strength of its ...

Editor's note: This story was corrected to note that Brooks will be Eli Lilly's interim CFO. A little more than a month after ...

While much of the attention on Novo Nordisk these days revolves around the company’s wildly popular GLP-1 drugs Ozempic and ...

Bayer’s massive reorganization championed by CEO Bill Anderson is bringing major changes to the German company’s pharma ...

A storm of scrutiny relating to Johnson & Johnson’s pricing and patenting of its tuberculosis med bedaquiline (branded as ...

Johnson & Johnson will pay Emergent BioSolutions $50 million to settle a two-year contract squabble and bring closure to an ...

Novo Nordisk’s massively successful GLP-1 analog semaglutide, the active ingredient in the popular diabetes and obesity meds ...

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits ...

Ahead of an election in November—and amid a period of legislative uncertainty for the China-targeting BIOSECURE Act—U.S.